002399 Shenzhen Hepalink Pharmaceutical Group
- 8.61
- -0.05-0.58%
Shenzhen Hepalink Pharmaceutical Group News
Shenzhen Hepalink Pharmaceutical Group: Announcement of Board Resolutions
Shenzhen Hepalink Pharmaceutical Group: Announcement on the renewal of accounting firms
Highpree: Investor Relations Activity Record Form for April 23, 2024
Hyperion: Announcement on holding the 2023 Annual Results Briefing
Hyperlink: Announcement on Responding to the Inquiry Letter on the 2023 Annual Report of the Shenzhen Stock Exchange
Hyperui: Special explanation from Ernst & Young Huaming Certified Public Accountants (Special General Partnership) on the Shenzhen Stock Exchange's “Inquiry Letter on the 2023 Annual Report of Shenzhen Haipuri Pharmaceutical Group Co., Ltd.” involving fina
Hyperlink: Correction Announcement on the Annual Special Audit Report on the Occupation of Related Party Funds
Hyperlink: Annual Special Audit Report on Related Party Capital Occupation (updated)
Highpree: 2023 Annual Audit Report
Hapley: Opinions of the Supervisory Board on the “Special Explanation of the Board of Directors on Matters Involving the Unqualified Audit Opinions with Highlighted Sections in the 2023 Internal Control Audit Report”
Hyperlink: Feasibility analysis report on developing foreign exchange derivatives transactions for hedging purposes
Highpree: Internal Control Audit Report
Hapley: Independent Director\'s 2023 Debriefing Report (Lu Chuan)
Highpree: Report on the evaluation report on the performance of accounting firms in 2023
Hyperlink: Annual Special Audit Report on Related Party Capital Occupation (before update)
Hapley: Independent Director's Annual Debriefing Report
Hyperion: Announcement on the results of an independent third party investigation
Hapley: Independent Director's 2023 Debriefing Report (Chen Junfa)
Highpree: Report on the work of the Supervisory Committee for the year 2023
Hapley: Independent Director's 2023 Debriefing Report (Yi Ming)
Analysis
Price Target
No Data
